# A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)

> **NCT01537900** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 4 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir

## Key facts

- **NCT ID:** NCT01537900
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2014-07-31
- **Final completion:** 2014-07-31
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01537900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01537900, "A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01537900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*